Добірка наукової літератури з теми "Evofosfamide"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Evofosfamide".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Evofosfamide"
Harms, Julia K., Tet-Woo Lee, Tao Wang, Amy Lai, Dennis Kee, John M. Chaplin, Nick P. McIvor, et al. "Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models." Cells 8, no. 7 (July 13, 2019): 717. http://dx.doi.org/10.3390/cells8070717.
Повний текст джерелаO'Connor, Liam J., Cindy Cazares-Körner, Jaideep Saha, Charles N. G. Evans, Michael R. L. Stratford, Ester M. Hammond, and Stuart J. Conway. "Efficient synthesis of 2-nitroimidazole derivatives and the bioreductive clinical candidate Evofosfamide (TH-302)." Organic Chemistry Frontiers 2, no. 9 (2015): 1026–29. http://dx.doi.org/10.1039/c5qo00211g.
Повний текст джерелаJayaprakash, Priyamvada, Meghan Rice, Krithikaa Rajkumar Bhanu, Brittany Morrow, Joseph Marszalek, Jason Gay, Christopher Vellano, Benjamin Cowen, Dean Welsch, and Michael Curran. "622 Disrupted oxygen supply and tumor hyper- oxygen consumption contribute independently to prostate cancer immune privilege." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A652. http://dx.doi.org/10.1136/jitc-2021-sitc2021.622.
Повний текст джерелаGrande, Enrique, Daniel E. Castellano, Ana B. Custodio, Rocio Garcia-Carbonero, Encarnación González, Carlos López-López, Javier Munarriz, et al. "A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial." Journal of Clinical Oncology 34, no. 4_suppl (February 1, 2016): TPS479. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.tps479.
Повний текст джерелаBailleul, Quentin, Pauline Navarin, Mélanie Arcicasa, Christine Bal-Mahieu, Angel Montero Carcaboso, Xuefen Le Bourhis, Alessandro Furlan, Samuel Meignan, and Pierre Leblond. "Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations." Cancers 13, no. 8 (April 9, 2021): 1804. http://dx.doi.org/10.3390/cancers13081804.
Повний текст джерелаLaubach, Jacob P., Noopur Raje, Andrew J. Yee, Philippe Armand, Robert L. Schlossman, Jacalyn Rosenblatt, Michael G. Martin, et al. "Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma." Blood 128, no. 22 (December 2, 2016): 2122. http://dx.doi.org/10.1182/blood.v128.22.2122.2122.
Повний текст джерелаHiggins, Jack P., Nenad Sarapa, Jason Kim, and Eric Poma. "Unexpected pharmacokinetics of evofosfamide observed in phase III MAESTRO study." Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018): 2568. http://dx.doi.org/10.1200/jco.2018.36.15_suppl.2568.
Повний текст джерелаPourmorteza, Mohsen, Zia U. Rahman, and Mark Young. "Evofosfamide, a new horizon in the treatment of pancreatic cancer." Anti-Cancer Drugs 27, no. 8 (September 2016): 723–25. http://dx.doi.org/10.1097/cad.0000000000000386.
Повний текст джерелаSpiegelberg, Linda, Stefan J. van Hoof, Rianne Biemans, Natasja G. Lieuwes, Damiënne Marcus, Raymon Niemans, Jan Theys, et al. "Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity." Radiotherapy and Oncology 141 (December 2019): 247–55. http://dx.doi.org/10.1016/j.radonc.2019.06.034.
Повний текст джерелаAnderson, Robert F., Dan Li, and Francis W. Hunter. "Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer." Free Radical Biology and Medicine 113 (December 2017): 564–70. http://dx.doi.org/10.1016/j.freeradbiomed.2017.10.385.
Повний текст джерелаДисертації з теми "Evofosfamide"
Liapis, Vasilios. "Targeting Cancer in the Bone with the Hypoxia Activated Pro-Drug Evofosfamide." Thesis, 2017. http://hdl.handle.net/2440/119332.
Повний текст джерелаThesis (Ph.D.) -- University of Adelaide, Adelaide Medical School, 2017
Тези доповідей конференцій з теми "Evofosfamide"
Meng, Fanying, Deepthi Bhupathi, Geraldine Chan, and Charles P. Hart. "Abstract 2803: Distinct roles of intracellular ROS in cisplatin and evofosfamide cytotoxicity." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-2803.
Повний текст джерелаNytko-Karouzakis, Katarzyna J., Ivo Grgic, Janosch Ott, and Martin Pruschy. "Abstract A163: The combined treatment modality of a hypoxia-activated prodrug (Evofosfamide) with ionizing radiation." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1535-7163.targ-15-a163.
Повний текст джерелаPerassi, Bruna Victorasso Jardim, Wei Mu, Dominique F. Abrahams, Michal R. Tomaszewski, Jan Poleszczuk, Jack Higgins, Gary V. Martinez, and Robert J. Gillies. "Abstract 2772: Targeting hypoxic habitats with hypoxia pro-drug evofosfamide in preclinical models of sarcoma." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-2772.
Повний текст джерелаHunter, Francis W., Avik Shome, Dan Li, Way W. Wong, Peter Tsai, Nooriyah Poonawala, Purvi M. Kakadiya, et al. "Abstract 169: Preclinical efficacy and sensitivity determinants of evofosfamide in molecularly defined models of head and neck squamous cell carcinoma." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-169.
Повний текст джерелаLavranos, Tina C., Daniel Inglis, Donna Beaumont, Annabell F. Leske, Chloe Hawkins, Michaela Scherer, Charles Hart, Jessica Sun, Brian Elenbaas, and Gabriel Kremmidiotis. "Abstract B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1535-7163.targ-15-b174.
Повний текст джерела